Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KHK | P50053 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9634877 | 0.89 | CHRM5 (0.45) | CHRM5CHRM3MEN1KMT2ASIGMAR1 | |
| SCHEMBL18538879 | 0.86 | MAPT (0.50) | MEN1KMT2ASIGMAR1MAPTPOLB | |
| SCHEMBL29300046 | 0.86 | — | — | |
| SCHEMBL17777943 | 0.82 | MAPT (0.57) | MEN1KMT2ASIGMAR1MAPTPOLB | |
| SCHEMBL5109896 | 0.82 | MAPT (0.62) | MEN1KMT2AMAPTPOLBHTT | |
| SCHEMBL23936816 | 0.81 | CHRM5 (0.43) | CHRM5CHRM3MEN1KMT2ASIGMAR1 | |
| SCHEMBL15032039 | 0.81 | HSD17B10 (0.46) | CHRM5CHRM3MEN1KMT2ASIGMAR1 | |
| SCHEMBL21214009 | 0.80 | SMN1; SMN2 (0.66) | CHRM5CHRM3MEN1KMT2ASIGMAR1 | |
| SCHEMBL255416 | 0.80 | CHRM5 (0.65) | CHRM5CHRM3MEN1KMT2ASIGMAR1 | |
| SCHEMBL14101799 | 0.80 | CHRM5 (0.65) | CHRM5CHRM3MEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-59020271-A | — | — | None | — | — | JP | disclosed |
| EP-4182322-B1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-04-24 | — | — | EP | disclosed |
| US-20240116947-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-04-11 | — | — | US | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| EP-4182322-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-05-24 | — | — | EP | disclosed |
| WO-2023014943-A1 | METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS | 4E THERAPEUTICS, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022013311-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-01-20 | — | — | WO | disclosed |
| WO-2022006331-A2 | PYRIDINE-1,5-DIONES EXHIBITNG MNK INHIBITION AND THEIR METHOD OF USE | 4E THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| EP-3475277-B1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-10-20 | — | — | EP | disclosed |
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| JP-S5920271-A | 1-AMINOCARBONYLETHYL-SUBSTITUTED PIPERAZINE AND HOMOPIPERAZINE DERIVATIVE | HOKURIKU SEIYAKU CO LTD | 1984-02-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116947-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | TGFBR1, ACVR1, TGFBR2 | CHRM5 368/4885CHRM3 1427/4885MEN1 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.